Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $21,387 | 5 | 67.8% |
| Travel and Lodging | $9,695 | 14 | 30.7% |
| Food and Beverage | $479.49 | 11 | 1.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Apellis Pharmaceuticals, Inc. | $9,209 | 10 | $0 (2024) |
| AstraZeneca UK Limited | $8,985 | 2 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $8,608 | 12 | $0 (2018) |
| Corium, LLC | $3,920 | 1 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $720.00 | 1 | $0 (2018) |
| Millennium Pharmaceuticals, Inc. | $70.94 | 1 | $0 (2017) |
| Novo Nordisk Inc | $19.27 | 1 | $0 (2024) |
| AbbVie Inc. | $19.04 | 1 | $0 (2021) |
| ARBOR PHARMACEUTICALS, INC. | $10.62 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,229 | 11 | Apellis Pharmaceuticals, Inc. ($9,209) |
| 2022 | $3,920 | 1 | Corium, LLC ($3,920) |
| 2021 | $19.04 | 1 | AbbVie Inc. ($19.04) |
| 2018 | $18,323 | 16 | AstraZeneca UK Limited ($8,985) |
| 2017 | $70.94 | 1 | Millennium Pharmaceuticals, Inc. ($70.94) |
All Payment Transactions
30 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Apellis Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| 12/20/2024 | Apellis Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| 12/20/2024 | Apellis Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $189.46 | General |
| 12/20/2024 | Apellis Pharmaceuticals, Inc. | — | Travel and Lodging | Cash or cash equivalent | $99.55 | General |
| 12/20/2024 | Apellis Pharmaceuticals, Inc. | — | Travel and Lodging | Cash or cash equivalent | $55.57 | General |
| 12/20/2024 | Apellis Pharmaceuticals, Inc. | — | Travel and Lodging | Cash or cash equivalent | $27.00 | General |
| 12/20/2024 | Apellis Pharmaceuticals, Inc. | — | Travel and Lodging | Cash or cash equivalent | $7.34 | General |
| 11/16/2024 | Apellis Pharmaceuticals, Inc. | — | Travel and Lodging | Cash or cash equivalent | $366.45 | General |
| 11/15/2024 | Apellis Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $111.02 | General |
| 10/08/2024 | Apellis Pharmaceuticals, Inc. | — | Travel and Lodging | Cash or cash equivalent | $552.95 | General |
| 07/28/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $19.27 | General |
| 12/07/2022 | Corium, LLC | Adlarity (Drug) | Consulting Fee | Cash or cash equivalent | $3,920.00 | General |
| Category: Treatment of dementia of the Alzheimers type | ||||||
| 02/19/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $19.04 | General |
| Category: NEUROSCIENCE | ||||||
| 12/13/2018 | ARBOR PHARMACEUTICALS, INC. | Horizant (Drug) | Food and Beverage | In-kind items and services | $10.62 | General |
| Category: Sleep | ||||||
| 05/22/2018 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $8,947.00 | General |
| 03/25/2018 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Travel and Lodging | In-kind items and services | $80.59 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/24/2018 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $80.18 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/24/2018 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Travel and Lodging | In-kind items and services | $32.42 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/24/2018 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $30.81 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/24/2018 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/23/2018 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $61.62 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/23/2018 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Travel and Lodging | In-kind items and services | $33.56 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/23/2018 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $30.81 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/23/2018 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/22/2018 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Travel and Lodging | In-kind items and services | $1,015.87 | General |
| Category: Cardiovascular and Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 69 | 69 | $44,636 | $11,791 |
| 2022 | 1 | 81 | 81 | $52,616 | $15,259 |
| 2021 | 1 | 88 | 95 | $60,620 | $18,701 |
| 2020 | 1 | 80 | 86 | $53,372 | $15,242 |
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99483 | Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | Office | 2023 | 69 | 69 | $44,636 | $11,791 | 26.4% |
| 99483 | Assessment of and care planning for impaired thought processing, typically 50 minutes | Office | 2022 | 81 | 81 | $52,616 | $15,259 | 29.0% |
| 99483 | Assessment of and care planning for patient with impaired thought processing, typically 50 minutes | Office | 2021 | 88 | 95 | $60,620 | $18,701 | 30.8% |
| 99483 | Assessment of and care planning for patient with impaired thought processing, typically 50 minutes | Office | 2020 | 80 | 86 | $53,372 | $15,242 | 28.6% |
About Russell Swerdlow
Russell Swerdlow is a Neurology healthcare provider based in Charlottesville, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942379581.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Russell Swerdlow has received a total of $31,561 in payments from pharmaceutical and medical device companies, with $9,229 received in 2024. These payments were reported across 30 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($21,387).
As a Medicare-enrolled provider, Swerdlow has provided services to 318 Medicare beneficiaries, totaling 331 services with total Medicare billing of $60,993. Data is available for 4 years (2020–2023), covering 4 distinct procedure/service records.
Practice Information
- Specialty Neurology
- Location Charlottesville, VA
- Active Since 11/07/2006
- Last Updated 07/26/2007
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1942379581
Products in Payments
- FARXIGA (Drug) $8,608
- Adlarity (Drug) $3,920
- UBRELVY (Drug) $19.04
- Horizant (Drug) $10.62
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Charlottesville
Dr. Robert Shin, M.d, M.D
Neurology — Payments: $2.3M
William Winter, Md, MD
Neurology — Payments: $954,731
Brian Weinshenker, M.d, M.D
Neurology — Payments: $249,928
Nathan Fountain
Neurology — Payments: $48,968
Helen Dainton-Howard, Md, MD
Neurology — Payments: $40,346
Alissa Higinbotham, Md, MD
Neurology — Payments: $35,843